查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081911

呼吸系統藥物市場：2026-2032年全球市場預測（按產品類型、給藥途徑、年齡層、適應症、最終用戶和分銷管道分類）

Pulmonary Drugs Market by Product Type, Route Of Administration, Age Group, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸系統藥物市場將成長至 400.1 億美元，複合年成長率為 8.48%。

主要市場統計數據
基準年 2025 226.2億美元
預計年份：2026年 246.8億美元
預測年份：2032年 400.1億美元
複合年成長率 (%) 8.48%

呼吸系統藥物市場概覽

由於慢性呼吸系統疾病、感染性肺部疾病和罕見肺血管疾病在全球範圍內造成的負擔日益加重，呼吸系統藥物市場格局正在改變。世界衛生組織（WHO）的數據顯示，慢性阻塞性肺病（COPD）是全球第三大死因，2019年造成323萬人死亡。同時，氣喘影響了約2.62億人，同年造成45.5萬人死亡。這些流行病學現實使得吸入型支氣管擴張劑、吸入型皮質類固醇、複方吸入劑、抗生素、抗纖維化藥物、生技藥品以及肺動脈高壓治療藥物的需求居高不下。

呼吸醫學領域的變革性變化

呼吸內科的治療模式正從廣泛的維持治療轉向以療效為導向的標靶治療。 GOLD 和 GINA 指引正在加速雙效支氣管擴張劑、選擇性吸入性糖皮質激素和生技藥品在特定類型重度氣喘的應用。同時，恩西芬特林（encifentrin）於 2024 年獲準用於治療慢性阻塞性肺病（COPD），這是First-in-Class獲準的吸入型 PDE3/PDE4 抑制劑。在肺動脈高壓領域，索他西普（sotatercept）於 2024 年獲得 FDA 批准，將治療模式從血管擴張擴展到靶向緩解疾病通道的干預措施。

人工智慧（AI）的累積影響

在呼吸系統領域，人工智慧（AI）正成為藥物發現、臨床開發和商業化各階段的強大驅動力。 AI 驅動的篩檢有助於識別藥物可分解的發炎、纖維化和血管相關靶點，而計算模型則支援吸入顆粒製劑、肺部沉積和設備性能的最佳化。在臨床試驗中，AI 擴大被用於透過影像學、肺功能測定趨勢、生物標記和電子健康記錄數據來提高患者選擇的準確性。

主要區域洞察：亞太地區、北美地區、歐洲地區、新興地區

亞太地區在呼吸系統藥物的長期需求中扮演著核心角色，這主要歸功於中國、印度、日本、韓國、澳洲和東協等市場龐大的患者群體，以及都市區空氣污染、吸菸和醫療保健覆蓋範圍不斷擴大等問題。儘管中國和印度由於空氣品質、生質能燃料暴露、吸煙和診斷不足等原因，呼吸系統疾病負擔尤為沉重，但日本、韓國和澳洲憑藉成熟的醫保報銷系統和專業的呼吸系統護理，正在率先採用生技藥品、肺動脈高壓治療藥物、抗纖維化藥物和先進的吸入平台。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

隨著各國政府致力於擴大全民健康納保、改善呼吸系統疾病診斷系統並提高吸入藥物的可近性，東協市場的重要性日益凸顯。然而，藥物價格、可靠的配送以及掌握正確的吸入技術仍然是關鍵障礙。海灣合作理事會（GCC）地區醫療保健投入高、專科醫院實力雄厚，且在沙烏地阿拉伯、阿拉伯聯合大公國、卡達及其鄰國推行的國家醫療現代化計畫的支持下，對氣喘、慢性阻塞性肺病（COPD）和肺動脈高壓的治療需求不斷成長。

主要呼吸系統藥物市場的關鍵國家洞察

美國在呼吸系統藥物創新方面處於領先地位，積極採用生物製藥治療氣喘、使用複方吸入劑治療慢性阻塞性肺病、治療肺動脈高壓，以及開發恩西芬特林和索他西普等新型療法。加拿大強調實證報銷和省級處方藥清單評估，而墨西哥和巴西則要求價格合理、公共部門分銷策略以及吸入維持治療藥物的可靠供應。在歐洲，英國、德國、法國、義大利和西班牙高度重視呼吸系統疾病，並進行嚴格的衛生技術評估（HTA）。尤其值得一提的是，德國和法國在專科藥物報銷、早期證據審查以及對真實世界數據（RWE）的期望方面發揮關鍵作用。

呼吸系統製藥行業領導者使用的實用建議

製藥供應商應優先考慮差異化的臨床證據，這些證據應能證明其產品可減少病情加重、改善肺功能、提高生活品質、延緩疾病進展（如適用）並降低醫療資源消耗。隨著支付方擴大將吸入聯合治療、生技藥品、抗纖維化藥物和肺動脈高壓提案與可衡量的療效、安全性、依從性和總醫療成本進行比較，具有說服力的價值主張至關重要。

調查方法

本執行摘要綜合運用了公共衛生數據、監管資訊、臨床指南趨勢和行業標準市場評估方法。主要證據來源包括世界衛生組織呼吸系統疾病統計數據、國家監管機構公告、同行評審的臨床文獻以及GOLD和GINA等組織的指南框架。

結論

呼吸系統藥物市場正朝著更精準、互聯和循證的時代邁進。儘管慢性阻塞性肺病、氣喘、肺動脈高壓、間質性肺病和感染性呼吸系統疾病仍產生著巨大的臨床需求，但生物製藥、First-in-Class小分子化合物、抗纖維化藥物和最佳化的吸入技術正在拓展治療選擇。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 呼吸系統藥物市場：依產品類型分類

  • 生物製劑
    • 抗IgE抗體
    • 抗IL-4/IL-13抑制劑
    • 抗IL-5/IL-5R抑制劑
  • 支氣管擴張劑
    • BETA-2促效劑
    • 抗膽鹼能藥物
    • 甲基黃嘌呤類類藥物
  • 聯合治療
  • 吸入性皮質類固醇
    • 倍氯米松
    • Budesonide
    • Fluticasone

第8章 呼吸系統藥物市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
  • 注射藥物
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 液體
    • 藥片

第9章 呼吸系統藥物市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第10章 呼吸系統藥物市場：依適應症分類

  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 囊腫纖維化
  • 間質性肺病
  • 肺纖維化
  • 肺動脈高壓
  • 呼吸道感染疾病

第11章 呼吸系統藥物市場：依最終用戶分類

  • 門診部
  • 居家照護
  • 醫院
  • 專科診所

第12章 呼吸系統藥物市場：依分銷管道分類

  • 物理藥房
  • 網路藥房

第13章 呼吸系統藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 呼吸系統藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 呼吸系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 4D Molecular Therapeutics, Inc.
  • AbbVie Inc.
  • Aer Therapeutics, Inc.
  • Aerogen Ltd.
  • Alembic Pharmaceuticals Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Bayer AG
  • Bespak Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • Cumberland Pharmaceuticals Inc.
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-4316E4E893EF

The Pulmonary Drugs Market is projected to grow by USD 40.01 billion at a CAGR of 8.48% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 22.62 billion
Estimated Year [2026] USD 24.68 billion
Forecast Year [2032] USD 40.01 billion
CAGR (%) 8.48%

Pulmonary Drugs Market Introduction

The pulmonary drugs market is being reshaped by the global burden of chronic respiratory disease, infectious lung disease, and rare pulmonary vascular disorders. The World Health Organization identifies COPD as the third leading cause of death worldwide, with 3.23 million deaths in 2019, while asthma affected an estimated 262 million people and caused 455,000 deaths in the same year. These epidemiological realities keep demand high for inhaled bronchodilators, inhaled corticosteroids, combination inhalers, antibiotics, antifibrotics, biologics, and pulmonary arterial hypertension therapies.

Growth is increasingly tied to precision respiratory medicine. Treatment decisions are moving beyond symptom control toward phenotype-guided asthma biologics, eosinophil-informed COPD care, antifibrotic intervention in progressive fibrosing lung disease, and guideline-based pulmonary hypertension management. For manufacturers, payers, and healthcare systems, competitive advantage now depends on clinical differentiation, adherence support, real-world evidence, sustainable inhaler portfolios, and access strategies that address both high-income markets and underserved respiratory populations.

Transformative Shifts in the Pulmonary Drug Landscape

The pulmonary drugs landscape is shifting from broad maintenance therapy to targeted, outcomes-oriented care. GOLD and GINA recommendations have accelerated the use of dual bronchodilation, selective inhaled corticosteroid use, and biologics for severe asthma phenotypes, while the 2024 U.S. approval of ensifentrine for COPD introduced a first-in-class inhaled PDE3/PDE4 option. In pulmonary arterial hypertension, the 2024 FDA approval of sotatercept expanded the treatment paradigm beyond vasodilation toward disease-modifying pathway intervention.

The market is also being transformed by delivery innovation and environmental pressure. Metered-dose inhalers remain essential, but manufacturers are responding to carbon-reduction policies by developing lower-global-warming-potential propellants and expanding dry-powder or soft-mist formats where clinically appropriate. At the same time, digital inhalers, remote monitoring, and adherence analytics are turning pulmonary drugs into connected therapeutic ecosystems rather than stand-alone prescriptions.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across pulmonary drug discovery, clinical development, and commercialization. AI-enabled screening can help identify druggable inflammatory, fibrotic, and vascular targets, while computational modeling supports formulation optimization for inhaled particles, lung deposition, and device performance. In clinical trials, AI is increasingly used to enrich patient selection through imaging, spirometry trends, biomarkers, and electronic health record data.

Regulatory oversight is evolving with adoption. The U.S. FDA has reported more than 300 drug and biologic submissions referencing AI or machine learning between 2016 and 2023, underscoring the need for transparent model validation and bias controls. For pulmonary drugs, the cumulative impact will be strongest where AI improves exacerbation prediction, adherence management, site selection, pharmacovigilance, and real-world evidence generation without replacing clinical judgment.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is central to long-term pulmonary drug demand because of large patient populations, urban air pollution exposure, tobacco use, and expanding healthcare access across China, India, Japan, South Korea, Australia, and ASEAN markets. China and India carry substantial respiratory disease burdens linked to air quality, biomass exposure, smoking, and underdiagnosis, while Japan, South Korea, and Australia support earlier adoption of biologics, pulmonary hypertension therapies, antifibrotics, and advanced inhalation platforms through mature reimbursement systems and specialist respiratory care.

North America remains a high-value pulmonary drugs market due to established guideline adoption, strong specialty care networks, FDA innovation pathways, and broad use of respiratory biologics, combination inhalers, and orphan pulmonary therapies. Europe benefits from coordinated clinical guidelines, mature pharmacovigilance, and health technology assessment discipline, while the European Union is increasingly influential in sustainable inhaler policy and low-carbon respiratory care. Latin America, led by Brazil and Mexico, shows rising demand for affordable inhaled therapies, stronger public-sector access, and biologics access programs for severe asthma and other high-need respiratory conditions. The Middle East, particularly GCC countries, is investing in specialty respiratory care, pulmonary hypertension programs, and hospital infrastructure, while Africa presents major access needs for asthma, COPD, tuberculosis-related lung disease, post-infectious respiratory impairment, and essential inhaled medicines.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining importance as governments expand universal health coverage, respiratory diagnostics, and access to essential inhaled medicines, although affordability, distribution reliability, and correct inhaler technique remain decisive barriers. The GCC is characterized by high healthcare investment, specialty hospital capacity, and growing demand for asthma, COPD, and pulmonary hypertension treatments, supported by national healthcare modernization programs in Saudi Arabia, the UAE, Qatar, and neighboring states.

The European Union shapes the pulmonary drugs market through centralized regulation, pharmacovigilance standards, health technology assessment, cross-border evidence expectations, and climate-focused inhaler policy. BRICS countries represent scale, manufacturing capability, and access challenges, particularly in China, India, Brazil, Russia, and South Africa, where respiratory disease burdens intersect with pricing pressure and local production priorities. G7 markets drive premium innovation, biologic uptake, rare pulmonary disease treatment adoption, and real-world evidence standards, while NATO member countries overlap with many high-income respiratory markets where supply resilience, essential medicines security, and domestic manufacturing are increasingly strategic priorities.

Key Country Insights Across Major Pulmonary Drug Markets

The United States leads in pulmonary drug innovation, with strong uptake of asthma biologics, COPD combination inhalers, pulmonary arterial hypertension therapies, and new options such as ensifentrine and sotatercept. Canada emphasizes evidence-based reimbursement and provincial formulary evaluation, while Mexico and Brazil require access-sensitive pricing, public-sector distribution strategies, and reliable availability of inhaled maintenance therapies. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high respiratory disease awareness with health technology assessment scrutiny; Germany and France are particularly important for specialty drug reimbursement, early evidence review, and real-world evidence expectations.

Russia remains a complex respiratory market affected by localization, supply continuity, and formulary considerations. China is expanding domestic innovation, regulatory modernization, respiratory specialty capacity, and access to advanced asthma, COPD, and pulmonary hypertension treatments, while India combines high respiratory disease burden with large generic manufacturing strength and demand for affordable inhalers. Japan, South Korea, and Australia support advanced care models, biologics, antifibrotics, and pulmonary hypertension therapies through mature regulatory systems, specialist networks, and high clinical guideline adherence.

Actionable Recommendations for Pulmonary Drug Leaders

Industry vendors should prioritize differentiated clinical evidence that demonstrates fewer exacerbations, better lung function, improved quality of life, slower disease progression where relevant, and reduced healthcare utilization. Strong value dossiers are essential because payers increasingly compare inhaled combinations, biologics, antifibrotics, and pulmonary hypertension therapies against measurable outcomes, safety, adherence, and total cost of care.

Companies should also invest in device usability, adherence support, patient education, and sustainable inhaler transitions without compromising patient technique or therapeutic equivalence. Portfolio strategies should balance premium biologics and specialty therapies with affordable essential medicines for emerging markets. Partnerships with diagnostics providers, digital health platforms, respiratory centers, and public health stakeholders can strengthen phenotype identification, trial recruitment, post-launch evidence generation, and equitable access to pulmonary drugs.

Research Methodology

This executive summary is based on triangulation of public health data, regulatory information, clinical guideline trends, and industry-standard market assessment practices. Core evidence sources include WHO respiratory disease statistics, national regulatory announcements, peer-reviewed clinical literature, and guideline frameworks from organizations such as GOLD and GINA.

The analysis evaluates pulmonary drugs by therapeutic class, disease area, delivery format, regulatory momentum, regional access conditions, sustainability considerations, and competitive differentiation. Insights are validated through cross-comparison of epidemiology, approvals, reimbursement dynamics, clinical adoption patterns, and real-world implementation factors to ensure that conclusions remain evidence-led, commercially relevant, and free from unsupported market sizing or forecasting assumptions.

Conclusion

The pulmonary drugs market is entering a more precise, connected, and evidence-intensive era. COPD, asthma, pulmonary arterial hypertension, interstitial lung disease, and infectious respiratory conditions continue to create substantial clinical need, while biologics, first-in-class small molecules, antifibrotics, and optimized inhalation technologies expand the treatment toolkit.

Future market leadership will depend on more than product efficacy alone. Organizations that integrate biomarker-driven care, AI-supported development, sustainable devices, equitable access, and robust real-world evidence will be best positioned to compete in a global respiratory therapeutics landscape shaped by both innovation and affordability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pulmonary Drugs Market, by Product Type

  • 7.1. Biologics
    • 7.1.1. Anti-IgE antibodies
    • 7.1.2. Anti-IL-4/IL-13 inhibitors
    • 7.1.3. Anti-IL-5 / IL-5R inhibitors
  • 7.2. Bronchodilators
    • 7.2.1. Beta-2 Agonists
    • 7.2.2. Anticholinergics
    • 7.2.3. Methylxanthines
  • 7.3. Combination Therapies
  • 7.4. Inhaled Corticosteroids
    • 7.4.1. Beclomethasone
    • 7.4.2. Budesonide
    • 7.4.3. Fluticasone

8. Pulmonary Drugs Market, by Route Of Administration

  • 8.1. Inhalation
    • 8.1.1. Dry Powder Inhalers
    • 8.1.2. Metered Dose Inhalers
    • 8.1.3. Nebulizers
  • 8.2. Injection
    • 8.2.1. Prefilled Syringes
    • 8.2.2. Vials
  • 8.3. Oral
    • 8.3.1. Capsules
    • 8.3.2. Liquids
    • 8.3.3. Tablets

9. Pulmonary Drugs Market, by Age Group

  • 9.1. Pediatric
  • 9.2. Adult
  • 9.3. Geriatric

10. Pulmonary Drugs Market, by Indication

  • 10.1. Asthma
  • 10.2. Chronic Obstructive Pulmonary Disease (COPD)
  • 10.3. Cystic Fibrosis
  • 10.4. Interstitial Lung Disease
  • 10.5. Pulmonary Fibrosis
  • 10.6. Pulmonary Hypertension
  • 10.7. Respiratory Infections

11. Pulmonary Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Homecare Settings
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Pulmonary Drugs Market, by Distribution Channel

  • 12.1. Offline Pharmacies
  • 12.2. Online Pharmacies

13. Pulmonary Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Pulmonary Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pulmonary Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 4D Molecular Therapeutics, Inc.
  • 17.2. AbbVie Inc.
  • 17.3. Aer Therapeutics, Inc.
  • 17.4. Aerogen Ltd.
  • 17.5. Alembic Pharmaceuticals Limited
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Avalyn Pharma Inc.
  • 17.9. Bayer AG
  • 17.10. Bespak Limited
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Chiesi Farmaceutici S.p.A.
  • 17.14. Cipla Limited
  • 17.15. Cumberland Pharmaceuticals Inc.
  • 17.16. Dr. Reddy's Laboratories Limited
  • 17.17. F. Hoffmann-La Roche Ltd
  • 17.18. GlaxoSmithKline plc
  • 17.19. Glenmark Pharmaceuticals Limited
  • 17.20. Insmed Incorporated
  • 17.21. Lupin Limited
  • 17.22. Merck & Co., Inc.
  • 17.23. Novartis AG
  • 17.24. Pfizer Inc.
  • 17.25. Sanofi S.A.
  • 17.26. Sun Pharmaceutical Industries Limited
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. Theravance Biopharma, Inc.
  • 17.29. Vertex Pharmaceuticals Incorporated
  • 17.30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PULMONARY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PULMONARY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-IGE ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-IL-4/IL-13 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-IL-5 / IL-5R INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BETA-2 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METHYLXANTHINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHYLXANTHINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METHYLXANTHINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMBINATION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALED CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BECLOMETHASONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BECLOMETHASONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BECLOMETHASONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BUDESONIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BUDESONIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BUDESONIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FLUTICASONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FLUTICASONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FLUTICASONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRY POWDER INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL METERED DOSE INHALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEBULIZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEBULIZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEBULIZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTERSTITIAL LUNG DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PULMONARY HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. GCC PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. G7 PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. G7 PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. NATO PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. NATO PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 281. NATO PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. NATO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. CANADA PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 329. BRAZIL PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 330. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 349. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 350. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 352. GERMANY PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 353. GERMANY PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 354. GERMANY PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 355. GERMANY PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 356. GERMANY PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 357. GERMANY PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 358. GERMANY PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 359. GERMANY PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 360. GERMANY PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 361. GERMANY PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 362. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 363. GERMANY PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 365. FRANCE PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. FRANCE PULMONARY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. FRANCE PULMONARY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 368. FRANCE PULMONARY DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 369. FRANCE PULMONARY DRUGS MARKET SIZE, BY INHALED CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 370. FRANCE PULMONARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 371. FRANCE PULMONARY DRUGS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 372. FRANCE PULMONARY DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 373. FRANCE PULMONARY DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 374. FRANCE PULMONARY DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 375. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 376. FRANCE PULMONARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 377. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 378. RUSSIA PULMONARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)